Latest treatment of multiple sclerosis Stories
Taking the new generation anti-inflammatory drug natalizumab for two years lowers the number of remitting multiple sclerosis patients who experience relapses and progression of disability.
ST. LOUIS, July 20, 2011 /PRNewswire/ -- Beginning July 29, Mark J.
Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) â€” a chronic inflammatory disease of the central nervous system.
Researchers from Mount Sinai School of Medicine will present several key studies at the American Academy of Neurology (AAN) annual meeting, including research providing critical insight into the prognosis and clinical treatment course of people with a certain subtype of Multiple Sclerosis (MS).
EAST HANOVER, N.J., April 11, 2011 /PRNewswire/ -- A new analysis demonstrated that Gilenya(TM) (fingolimod) reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history.
2010: A Year of Significant Progress in MS Research (Vocus/PRWEB) December 20, 2010 Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS.
National MS Society Leads the Way in Cutting Edge Research to Stop MS, Restore Function and End MS Forever NEW YORK, Dec. 20, 2010 /PRNewswire-USNewswire/ -- Exciting advances were made in 2010 in virtually every field of MS research.
EXTON, Pa., Dec. 6, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that surveyed neurologists indicate that their initial trial of Novartis's Gilenya has been hampered by potential safety / tolerability concerns and monitoring requirements.
BURLINGTON, Mass., Dec. 1, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that less than 30 percent of surveyed relapsing-remitting multiple sclerosis (MS) patients in the U.S.
- Large; stout; burly.